AC Immune (NASDAQ:ACIU) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of AC Immune (NASDAQ:ACIU) have been assigned a consensus recommendation of “Hold” from the five analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $7.50.

Several analysts have recently issued reports on the stock. BTIG Research reiterated a “buy” rating and issued a $8.00 target price on shares of AC Immune in a research report on Monday, May 4th. HC Wainwright reaffirmed a “buy” rating on shares of AC Immune in a research note on Wednesday, July 1st. Finally, Weiss Ratings cut AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 8th.

Insider Buying and Selling at AC Immune

In other news, CEO Andrea Pfeifer sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $2.79, for a total value of $27,900.00. Following the transaction, the chief executive officer owned 3,820,288 shares in the company, valued at $10,658,603.52. This trade represents a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. EFG International AG purchased a new position in AC Immune in the 4th quarter valued at $41,000. Private Advisor Group LLC acquired a new stake in shares of AC Immune in the third quarter valued at about $48,000. Sei Investments Co. acquired a new stake in shares of AC Immune in the second quarter valued at about $51,000. Goldman Sachs Group Inc. lifted its stake in shares of AC Immune by 46.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock worth $58,000 after buying an additional 5,920 shares in the last quarter. Finally, Susquehanna International Group LLP purchased a new position in shares of AC Immune in the third quarter worth about $63,000. 51.36% of the stock is owned by institutional investors and hedge funds.

AC Immune Trading Down 0.4%

Shares of ACIU stock opened at $2.23 on Friday. AC Immune has a 1-year low of $2.03 and a 1-year high of $4.00. The company has a market cap of $226.95 million, a price-to-earnings ratio of -2.72 and a beta of 1.57. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.87 and a quick ratio of 1.02. The stock has a 50 day simple moving average of $2.47 and a 200-day simple moving average of $2.85.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.01. The company had revenue of $1.40 million during the quarter, compared to analyst estimates of $0.33 million. AC Immune had a negative net margin of 1,788.02% and a negative return on equity of 125.26%. On average, equities research analysts expect that AC Immune will post -0.84 EPS for the current fiscal year.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.